The effectiveness clears the way for Nasus Pharma to price its IPO, likely within 1-2 days. Given the company's pre-revenue status and going-concern warning, the IPO's success depends entirely on investor appetite for a high-risk clinical-stage biotech. Monitor for the pricing announcement and subsequent trading debut — a weak IPO could signal limited institutional support.
Price Chart
Executive Summary
Nasus Pharma's F-1 registration statement (File No. 333-293950) was declared effective by the SEC on August 20, 2026, enabling the company to proceed with its IPO of securities. The effectiveness clears the regulatory path for the clinical-stage biotech to begin trading, though the offering size, price, and timing remain undisclosed in this notice. The company has no revenue, is pre-commercial, and faces a going-concern risk without additional funding, making this a critical liquidity event.
Key Facts
- SEC declared F-1 registration effective on August 20, 2026 (File No. 333-293950).
- Nasus Pharma is a clinical-stage Israeli pharmaceutical company developing intranasal epinephrine (NS002) for anaphylaxis.
- The company has no revenue, has incurred significant losses, and faces substantial doubt about its ability to continue as a going concern without additional funding.
- Offering size, price, and timing are not specified in the EFFECT filing.
Financial Impact
Undisclosed offering size — IPO proceeds are critical for funding operations and clinical development of NS002.
Risk Factors
- IPO may fail to raise sufficient capital to fund operations through key clinical milestones.
- Going-concern risk remains if IPO proceeds are inadequate or delayed.
- Clinical-stage pipeline (NS002) has not been powered for statistical significance in early trials.
- No revenue and significant historical losses create high execution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002715 |
| Document: 9999999995-26-002715-index.html | 9999999995-26-002715 |
| Document: 9999999995-26-002715.txt | 9999999995-26-002715 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.51 | awaiting T+20 | — | $3.49 (−0.57%) |
Sep 23, 2026 4w ago | 3 | $3.64 $3.06 | ▼ −15.93% | ▼ −16.62% | $3.49 (−4.12%) |
Sep 18, 2026 5w ago | 424B5 | $3.44 $3.21 | ▲ +6.83% | ▲ +5.92% | $3.49 (−1.45%) |
Sep 14, 2026 6w ago | 6-K | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.49 (−4.38%) |
Sep 14, 2026 6w ago | EFFECT | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.49 (−4.38%) |
Aug 21, 2026 9w ago | EFFECT | $4.00 $3.44 | ▼ −14.00% | ▼ −13.47% | $3.49 (−12.75%) |
Aug 19, 2026 9w ago | 6-K | $3.84 $3.53 | ▼ −8.07% | ▼ −6.12% | $3.49 (−9.11%) |
Aug 17, 2026 10w ago | 6-K | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.49 (−5.68%) |
Aug 17, 2026 10w ago | Press Release | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.49 (−5.68%) |
Apr 1, 2026 29w ago | EFFECT | $2.55 $2.56 | ▼ −0.39% | ▲ +9.33% | $3.49 (−36.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers